Document Detail


Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors.
MedLine Citation:
PMID:  20804743     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a promising anticancer agent but cutaneous T lymphoma cells (CTCL) are less sensitive to TRAIL-induced apoptosis. Here, we report that pentoxifylline (PTX), a phosphodiesterase inhibitor, augments TRAIL-mediated apoptosis in HuT-78 and MyLa cells through modulating extrinsic death receptors and intrinsic mitochondria dependent pathways. Our results clearly show that PTX augments TRAIL-mediated activation of caspase-8 and induces cleavage of Bid, although PTX alone cannot activate caspase-8. This is followed by cytochrome c release and subsequent, activation of caspase-9 and caspase-3 and cleavage of poly (ADP ribose) polymerase (PARP). Combined treatment downregulates the expression of various antiapoptotic proteins including c-FLIP, Bcl-xl, cIAP-1, cIAP-2 and XIAP. PTX induces the expression of death receptors DR4 and DR5 on cell surface of both the cell types where c-Jun NH2-terminal kinase (JNK) pathway plays an important role. Moreover, combined silencing of DR4 and DR5 by small interfering RNA abrogates the ability of PTX to induce TRAIL-mediated apoptosis. Thus, this is the first demonstration that PTX can potentiate TRAIL-mediated apoptosis through downregulation of cell survival gene products and upregulation of death receptors.
Authors:
Satindra Gahlot; Mohammad Aslam Khan; Loveena Rishi; Sekhar Majumdar
Related Documents :
15579063 - Tnf-related apoptosis-inducing ligand (trail): a potential candidate for combined treat...
16123163 - Death ligand tumor necrosis factor-related apoptosis-inducing ligand inhibits experimen...
18562213 - Modulation of the immune system of fish by their environment.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-08
Journal Detail:
Title:  Biochemical pharmacology     Volume:  80     ISSN:  1873-2968     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-18     Completed Date:  2010-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1650-61     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Division of Cell Biology and Immunology, Institute of Microbial Technology (CSIR), Chandigarh 160036, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Pharmaceutic / pharmacology*
Apoptosis / drug effects,  physiology*
Apoptosis Regulatory Proteins / biosynthesis*,  physiology
Cell Line, Tumor
Drug Synergism
Gene Expression Regulation, Neoplastic / drug effects*,  physiology
Humans
Lymphoma, T-Cell, Cutaneous / metabolism,  pathology*
Pentoxifylline / pharmacology*
Receptors, Death Domain / biosynthesis*,  physiology
TNF-Related Apoptosis-Inducing Ligand / physiology*
Chemical
Reg. No./Substance:
0/Adjuvants, Pharmaceutic; 0/Apoptosis Regulatory Proteins; 0/Receptors, Death Domain; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFSF10 protein, human; 6493-05-6/Pentoxifylline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously...
Next Document:  Electrophysiological correlates of the masked translation priming effect with highly proficient simu...